E2080 ( DrugBank: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
144	レノックス・ガストー症候群	6

144. レノックス・ガストー症候群

臨床試験数 : 111 / 薬物数 : 72 - (DrugBank : 14) / 標的遺伝子数 : 49 - 標的パスウェイ数 : 61

diseases per page:

Showing 1 to 6 of 6 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03778424 (ClinicalTrials.gov)	April 17, 2019	27/11/2018	An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303 ...	An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controll ...	Lennox Gastaut Syndrome	Drug: Rufinamide	Eisai Inc.	NULL	Available	4 Years	N/A	All			Poland
2	EUCTR2010-023505-36-IT (EUCTR)	29/09/2011	05/01/2012	A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effect ...	A Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Cognitive Development Effect ...	Lennox Gastaut Syndrome MedDRA version: 14.1;Level: PT;Classification code 10048816;Term: Lennox-Gas ...	Trade Name: Inovelon Other descriptive name: Rufinamide oral suspension INN or Proposed INN: lamotrigi ...	EISAI LTD UK	NULL	Not Recruiting			Female: yes Male: yes	75		Greece;Italy
3	NCT01151540 (ClinicalTrials.gov)	November 2010	14/6/2010	A Long Term Extension Study of E2080 in Lennox-Gastaut Patients	A Long Term Extension Study of E2080 in Lennox-Gastaut Patients	Lennox-Gastaut Syndrome	Drug: Rufinamide	Eisai Co., Ltd.	NULL	Completed	4 Years	30 Years	All	54	Phase 3	Japan
4	NCT01146951 (ClinicalTrials.gov)	June 2010	14/6/2010	A Placebo-Controlled, Double-Blind Comparative Study of E2080in Lennox-Gastaut Syndrome Patients (St ...	A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients	Lennox-Gastaut Syndrome	Drug: Rufinamide (E2080);Drug: Placebo	Eisai Limited	NULL	Completed	4 Years	30 Years	All	66	Phase 3	Japan
5	EUCTR2016-004953-34-Outside-EU/EEA (EUCTR)		23/02/2017	A Long Term Extension Study of E2080 in Patients with Lennox-GastautSyndrome	A Long Term Extension Study of E2080 in Patients with Lennox-GastautSyndrome	Lennox-Gastaut Syndrome;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Inovelon Product Name: rufinamide Product Code: E2080 INN or Proposed INN: RUFINAMIDE	Eisai Co, Ltd.	NULL	NA			Female: yes Male: yes	54	Phase 3	Japan
6	EUCTR2016-004952-30-Outside-EU/EEA (EUCTR)		13/02/2017	A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients	A Placebo-Controlled, Double-Blind Comparative Study of E2080 in Lennox-Gastaut Syndrome Patients	Lennox-Gastaut Syndrome (LSG);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Inovelon Product Name: rufinamide Product Code: E2080 INN or Proposed INN: RUFINAMIDE	Eisai Co, Ltd.	NULL	NA			Female: yes Male: yes	58	Phase 3	Japan

First Previous1Next Last